share_log
Reuters ·  May 9 07:08
Bluebird bio-Sees 85 to 105 Patient Starts(Cell Collections) Combined Across All 3 of Its FDA Approved Therapies (Lyfgenia,Zynteglo, Skysona) in 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment